Skip to main content

Drug Interactions between rifampin and vamorolone

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

rifAMPin vamorolone

Applies to: rifampin and vamorolone

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with strong inducers of CYP450 3A4 or the pregnane X receptor (PXR) (e.g. carbamazepine, phenytoin, rifampin, St. John's wort) may decrease the plasma concentrations of vamorolone leading to a lack of efficacy. Vamorolone is partially metabolized in vitro by CYP3A4. The clinical significance of this interaction is unknown.

MANAGEMENT: Some authorities recommend considering the use of alternative treatments that are not strong inducers of CYP3A4 during concomitant use with vamorolone due to reduced vamorolone efficacy. No dose adjustments are recommended. The possibility of decreased corticosteroid effects should be considered. Patients should be monitored for signs and symptoms of steroid withdrawal and secondary renal insufficiency, including anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma).

Drug and food interactions

Moderate

rifAMPin food

Applies to: rifampin

Food can decrease the levels of rifAMPin in your body. Taking rifAMPin on an empty stomach (at least 30 minutes before or 2 hours after a meal) will make it easier for your body to absorb the medication. Avoid drinking alcohol while taking rifAMPin because alcohol use may increase the risk of damage to your liver. It is important to seek immediate medical care if you experience any severe side effects or symptoms of liver damage such as fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

vamorolone food

Applies to: vamorolone

Grapefruit juice may increase the blood levels and effects of vamorolone. This may increase the risk and/or severity of side effects such as swelling, weight gain, electrolyte abnormalities, high blood pressure, high blood glucose, muscle weakness, depression, mood swings, acne, thinning skin, stretch marks, easy bruising, cataracts, glaucoma, excessive growth of facial or body hair, and abnormal distribution of body fat, especially in the face, neck, back, and waist. Other side effects that may occur include decreased ability to fight infections, increased risk of developing infections, and inadequate response to stress such as infection, surgery, trauma, or a severe asthma attack. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.